Multidimensional scaling as a tool for analysing quality of life data.

Kemmler, G; Holzner, B; Kopp, M; Dünser, M; Greil, R; Hahn, E; Sperner-Unterweger, B; Qual Life Res. 2002; 11(3): 22-33.

Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura.

Gadenstätter, M; Lamprecht, B; Klingler, A; Wetscher, GJ; Greil, R; Schmid, T; Am J Surg. 2002; 184(6): 606-609.

Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.

Jakesz, R; Hausmaninger, H; Samonigg, H; Eur J Cancer. 2002; 38(3): 327-332.

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.

Jäger, G; Neumeister, P; Brezinschek, R; Hinterleitner, T; Fiebiger, W; Penz, M; Neumann, HJ; Mlineritsch, B; DeSantis, M; Quehenberger, F; Chott, A; Beham-Schmid, C; Höfler, G; Linkesch, W; Raderer, M; J Clin Oncol. 2002; 20(18): 3872-3877.

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5.

Jakesz, R; Hausmaninger, H; Kubista, E; Gnant, M; Menzel, C; Bauernhofer, T; Seifert, M; Haider, K; Mlineritsch, B; Steindorfer, P; Kwasny, W; Fridrik, M; Steger, G; Wette, V; Samonigg, H; J Clin Oncol. 2002; 20(24):4621-4627

The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.

Schwarzmeier, JD; Shehata, M; Hilgarth, M; Marschitz, I; Louda, N; Hubmann, R; Greil, R; Leuk Lymphoma. 2002; 43(3): 549-554.

Monoclonal gammopathy of undetermined significance.

Fiegl, M; Greil, R; N Engl J Med. 2002; 346(26): 2087-2088.

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.

Crazzolara, R; Jöhrer, K; Johnstone, RW; Greil, R; Kofler, R; Meister, B; Bernhard, D; Br J Haematol. 2002; 119(4): 965-969.

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.

Hilbe, W; Kühr, T; Apfelbeck, U; Fridrik, M; Seewann, H; Stöger, M; Linkesch, W; Pont, J; Baldinger, C; Hartner, E; Bernhart, M; Geissler, D; Krieger, O; Lang, A; Lin, W; Ludwig, H; Duba, C; Greil, R; Gast, G; Thaler, J; Leuk Lymphoma. 2002; 42(6): 1283-1288.

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.

Anether, G; Marschitz, I; Tinhofer, I; Greil, R; Blood. 2002; 99(2): 722-723.